2023 World Conference on Lung Cancer (Posters)-EP13.04. Characterization of Limited-Stage Small Cell Lung Cancer: Molecular Subtypes, Tumor Microenvironment and Clinical Follow-up

EP13.04. Characterization of Limited-Stage Small Cell Lung Cancer: Molecular Subtypes, Tumor Microenvironment and Clinical Follow-up - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to characterize limited-stage small cell lung cancer (SCLC) by examining molecular subtypes, tumor microenvironment, and clinical outcomes. The researchers analyzed surgically resected limited-stage SCLC cases from 2000-2022, using immunohistochemistry to subtype the tumors and assess lymphocytic infiltrates. The study cohort consisted of 30 limited-stage SCLC cases, with most cases pathologically staged as I (37%), II (33%), and III (30%) diseases. The molecular subtypes identified were ASCL1-dominant (63%), NEUROD1-dominant (23%), POU2F3-positive (10%), and triple-negative (3%). All SCLC-P and SCLC-TN cases showed minimal neuroendocrine marker positivity. The lymphocytic infiltrates were primarily T-cells, with higher CD8/CD4 ratios observed in the SCLC-P and SCLC-TN groups. B-cell counts were lower in the SCLC-P and SCLC-TN groups. Median progression-free survival (PFS) varied among the subtypes, with SCLC-A at 13.6 months, SCLC-N at 10.9 months, and SCLC-TN at 1.5 months. Median overall survival (OS) was 27.1 months for SCLC-A, 49.9 months for SCLC-N, and 10.2 months for SCLC-TN. The study provides novel insights into the molecular subtypes and tumor microenvironment of limited-stage SCLC. The most common subtype was SCLC-A, and the tumor lymphocytic infiltrate consisted mainly of T-cells. The CD8/CD4 ratio was higher in the SCLC-P and SCLC-TN groups. Further research is ongoing to investigate the tumor microenvironment in more detail. This study contributes to the understanding of limited-stage SCLC and may have implications for the development of personalized treatment approaches.

Asset Subtitle

Guoping Cai

Meta Tag

Speaker Guoping Cai

Topic SCLC & Neuroendocrine Tumors: LS-SCLC

Keywords

limited-stage small cell lung cancer

molecular subtypes

tumor microenvironment

clinical outcomes

lymphocytic infiltrates

pathological staging

neuroendocrine marker positivity

T-cells

progression-free survival

personalized treatment approaches